Professor Richard Haynes
Research groups
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ASCEND: A Study of Cardiovascular Events iN Diabetes
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- HPS2 -THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- SHARP: Study of Heart and Renal Protection
- Trials Methodology
- UK HARP III
- Genetic determinants of chronic kidney disease progression
- Mexico City Prospective Study: mapping genetic risk factors of major non-communicable diseases (MRC-PHRU)
Websites
-
MRC Population Health Research Unit
Programme Leader
Richard Haynes
DM, MRCP
Professor of Renal Medicine and Clinical Trials
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease.
Recent publications
-
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2022)
-
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Journal article
Staplin N. et al, (2022), Hypertension
-
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
-
The Health and Care Act 2022: key challenges and priority actions for embedding research in the NHS
Other
HAYNES R., (2022), The Lancet
-
Allocated but not treated: the silent 16% - Authors' reply.
Other
Horby P. et al, (2022), Lancet, 399, 1775 - 1776